Sildenafil citrate is under clinical development by Dare Bioscience and currently in Phase II for Female Hypoactive Sexual Desire Disorder. According to GlobalData, Phase II drugs for Female Hypoactive Sexual Desire Disorder have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sildenafil citrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sildenafil citrate overview
Sildenafil citrate (SST-6007) is under development for the treatment of female hypoactive sexual desire disorder. The drug candidate is a small molecule applied vaginally. It acts by targeting phosphodiesterase 5 (PDE-5). It is developed based on KNOSIS delivery technology.
Dare Bioscience overview
Dare Bioscience, formerly Cerulean Pharma, is a biopharmaceutical company that develops products for women’s reproductive health. The company, through its dynamic tumor targeting platform, creates nanoparticle drug conjugates to attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. It offers products that include ovaprene, a clinical stage, non-hormonal contraceptive ring that provides protection over multiple weeks of use; and topical 5% sildenafil citrate cream for women with female sexual arousal disorders. The company develops and markets therapies for women in the areas of contraception, vaginal health, sexual health and fertility. It offers services across the US. Dare Bioscience is headquartered in San Diego, California, the US.
For a complete picture of Sildenafil citrate’s drug-specific PTSR and LoA scores, buy the report here.